Triple negative breast cancer (TNBC), the most aggressive breast cancer type, is associated with high mortality and recurrence rates. An active-targeted strategy based on homing peptides is an effective approach to diagnose and treat cancer as it can deliver imaging agents or therapeutic drugs into desired tissues and accumulate less into off-target tissues. As a homing peptide, LyP-1 has shown properties of targeting, internalization, and proapoptosis to TNBC. In the study, we designed a Technetium-99m- (99mTc-) labeled LyP-1 and investigated its feasibility for targeted single-positron emission computed tomography (SPECT) imaging of TNBC. The results showed that the LyP-1 peptide had acceptable biocompatibility in the studied concentration range and could specifically bind to TNBC cells in vitro. 99mTc-labeled LyP-1 showed high radiochemical purity and stability and could be used as a probe for targeted SPECT imaging of TNBC cells in vitro and in a TNBC tumor-bearing mouse model. Our findings indicate that this active-targeted strategy has great potential to be developed into a new imaging tool for TNBC diagnosis.

中文翻译：

---

99mTc标记的LyP-1用于三阴性乳腺癌的SPECT成像。

三阴性乳腺癌（TNBC）是最具侵略性的乳腺癌类型，与高死亡率和复发率相关。基于归巢肽的主动靶向策略是诊断和治疗癌症的有效方法，因为它可以将成像剂或治疗药物输送到所需的组织中，而较少地积累到脱靶组织中。作为归巢肽，LyP-1已显示出靶向，内化和向TNBC凋亡的特性。在这项研究中，我们设计了标记为LyP-1的Technetium-99m-（99mTc-），并研究了其用于TNBC的靶向单正电子发射计算机断层扫描（SPECT）成像的可行性。结果表明，LyP-1肽在所研究的浓度范围内具有可接受的生物相容性，并且可以在体外特异性结合TNBC细胞。99mTc标记的LyP-1具有很高的放射化学纯度和稳定性，可以用作体外和TNBC荷瘤小鼠模型中TNBC细胞靶向SPECT成像的探针。我们的发现表明，这种主动靶向策略具有巨大的潜力，可以被开发为TNBC诊断的新成像工具。